Compare STEL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | ZYME |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | 1053 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2017 | 2022 |
| Metric | STEL | ZYME |
|---|---|---|
| Price | $36.93 | $24.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $37.00 | ★ $38.90 |
| AVG Volume (30 Days) | 220.9K | ★ 539.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 0.53 | N/A |
| Revenue | $6,282,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $10.14 | $183.10 |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | $68.62 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $26.08 | $11.02 |
| 52 Week High | $40.21 | $29.75 |
| Indicator | STEL | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 42.34 |
| Support Level | $36.95 | $22.50 |
| Resistance Level | $38.10 | $27.54 |
| Average True Range (ATR) | 0.59 | 1.25 |
| MACD | -0.12 | -0.39 |
| Stochastic Oscillator | 41.94 | 24.19 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc. and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.